Literature DB >> 18791454

Amelioration of human allograft arterial injury by atorvastatin or simvastatin correlates with reduction of interferon-gamma production by infiltrating T cells.

Tai Yi1, Deepak A Rao, Paul C Y Tang, Yinong Wang, Lisa A Cuchara, Alfred L M Bothwell, Christopher M Colangelo, George Tellides, Jordan S Pober, Marc I Lorber.   

Abstract

BACKGROUND: Graft arteriosclerosis (GA) is an important factor limiting long-term outcomes after organ transplantation. We have used a chimeric humanized mouse system to model this arteriopathy in human vessels, and found that the morphologic and functional changes of experimental GA are interferon (IFN)-gamma dependent. This study evaluated whether 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, described as inhibitors of IFN-gamma production, affect GA in our model.
METHODS: C.B.-17 severe combined immunodeficiency-beige mice were transplanted with human artery segments as aortic interposition grafts and inoculated with allogeneic human peripheral blood mononuclear cells (PBMCs) or replication-deficient adenovirus encoding human IFN-gamma. Transplant arteries were analyzed from recipients treated with vehicle vs. atorvastatin or simvastatin at different doses. The effects of statins on T-cell alloresponses to vascular endothelial cells were also investigated in vitro.
RESULTS: Graft arteriosclerosis-like arteriopathy induced by PBMCs was reduced by atorvastatin at 30 mg/kg/day or simvastatin at 100 mg/kg/day that correlated with decreased graft-infiltrating CD3+ T cells. Circulating IFN-gamma was also reduced, as were graft IFN-gamma and IFN-gamma-inducible chemokine transcripts and graft human leukocyte antigen-DR expression. Graft arteriosclerosis directly induced by human IFN-gamma in the absence of human PBMCs was also reduced by atorvastatin, but only at the highest dose of 100 mg/kg/day. Finally, atorvastatin decreased the clonal expansion and production of interleukin-2, but not IFN-gamma, by human CD4+ T cells in response to allogeneic endothelial cells in coculture.
CONCLUSIONS: Our results suggest that a benefit of statin administration in transplantation may include amelioration of GA primarily by inhibiting alloreactive T-cell accumulation and consequent IFN-gamma production and secondarily through suppression of the arterial response to IFN-gamma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18791454      PMCID: PMC2650813          DOI: 10.1097/TP.0b013e318183eefa

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  25 in total

Review 1.  Statins: effects beyond cholesterol lowering.

Authors:  Z A Massy; C Guijarro
Journal:  Nephrol Dial Transplant       Date:  2001-09       Impact factor: 5.992

Review 2.  Chronic rejection.

Authors:  P Libby; J S Pober
Journal:  Immunity       Date:  2001-04       Impact factor: 31.745

3.  Interferon-gamma elicits arteriosclerosis in the absence of leukocytes.

Authors:  G Tellides; D A Tereb; N C Kirkiles-Smith; R W Kim; J H Wilson; J S Schechner; M I Lorber; J S Pober
Journal:  Nature       Date:  2000-01-13       Impact factor: 49.962

4.  Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients.

Authors:  Robert L Lins; Katelijne E Matthys; Gert A Verpooten; Patrick C Peeters; Max Dratwa; Jean-Claude Stolear; Norbert H Lameire
Journal:  Nephrol Dial Transplant       Date:  2003-05       Impact factor: 5.992

5.  An inflammatory pathway of IFN-gamma production in coronary atherosclerosis.

Authors:  Hooman Ranjbaran; Seth I Sokol; Amy Gallo; Raymond E Eid; Alexander O Iakimov; Alessio D'Alessio; John R Kapoor; Shamsuddin Akhtar; Christopher J Howes; Mihaela Aslan; Steven Pfau; Jordan S Pober; George Tellides
Journal:  J Immunol       Date:  2007-01-01       Impact factor: 5.422

6.  The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease.

Authors:  Sawsan Youssef; Olaf Stüve; Juan C Patarroyo; Pedro J Ruiz; Jennifer L Radosevich; Eun Mi Hur; Manuel Bravo; Dennis J Mitchell; Raymond A Sobel; Lawrence Steinman; Scott S Zamvil
Journal:  Nature       Date:  2002-11-07       Impact factor: 49.962

Review 7.  Cardiac allograft vasculopathy: central role of endothelial injury leading to transplant "atheroma".

Authors:  Hannah A Valantine
Journal:  Transplantation       Date:  2003-09-27       Impact factor: 4.939

8.  Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients.

Authors:  Howard J Eisen; E Murat Tuzcu; Richard Dorent; Jon Kobashigawa; Donna Mancini; Hannah A Valantine-von Kaeppler; Randall C Starling; Keld Sørensen; Manfred Hummel; Joan M Lind; Kamal H Abeywickrama; Peter Bernhardt
Journal:  N Engl J Med       Date:  2003-08-28       Impact factor: 91.245

Review 9.  Interferon-gamma axis in graft arteriosclerosis.

Authors:  George Tellides; Jordan S Pober
Journal:  Circ Res       Date:  2007-03-16       Impact factor: 17.367

Review 10.  Immunopathology of human T cell responses to skin, artery and endothelial cell grafts in the human peripheral blood lymphocyte/severe combined immunodeficient mouse.

Authors:  Jordan S Pober; Alfred L M Bothwell; Marc I Lorber; Jennifer M McNiff; Jeffrey S Schechner; George Tellides
Journal:  Springer Semin Immunopathol       Date:  2003-09
View more
  9 in total

Review 1.  Impact of environmental factors on alloimmunity and transplant fate.

Authors:  Leonardo V Riella; Jessamyn Bagley; John Iacomini; Maria-Luisa Alegre
Journal:  J Clin Invest       Date:  2017-05-08       Impact factor: 14.808

2.  Statin-induced Krüppel-like factor 2 expression in human and mouse T cells reduces inflammatory and pathogenic responses.

Authors:  De-xiu Bu; Margarite Tarrio; Nir Grabie; Yuzhi Zhang; Hiroyuki Yamazaki; George Stavrakis; Elena Maganto-Garcia; Zachary Pepper-Cunningham; Petr Jarolim; Masanori Aikawa; Guillermo García-Cardeña; Andrew H Lichtman
Journal:  J Clin Invest       Date:  2010-05-03       Impact factor: 14.808

Review 3.  Impact of hyperlipidemia on alloimmunity.

Authors:  Jessamyn Bagley; Jin Yuan; John Iacomini
Journal:  Curr Opin Organ Transplant       Date:  2017-02       Impact factor: 2.640

Review 4.  Interacting mechanisms in the pathogenesis of cardiac allograft vasculopathy.

Authors:  Jordan S Pober; Dan Jane-wit; Lingfeng Qin; George Tellides
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-06-05       Impact factor: 8.311

5.  Peroxisome proliferator-activated receptor-γ agonists prevent in vivo remodeling of human artery induced by alloreactive T cells.

Authors:  Zuzana Tobiasova; Lufeng Zhang; Tai Yi; Linfeng Qin; Thomas D Manes; Sanjay Kulkarni; Marc I Lorber; Frederick C Rodriguez; Je-Min Choi; George Tellides; Jordan S Pober; Ivana Kawikova; Alfred L M Bothwell
Journal:  Circulation       Date:  2011-06-20       Impact factor: 29.690

6.  Randomized clinical trial: atorvastatin versus placebo in patients with acute exacerbation of mild to moderate ulcerative colitis.

Authors:  Puneet Dhamija; Debasish Hota; Rakesh Kochhar; Atul Sachdev; Amitava Chakrabarti
Journal:  Indian J Gastroenterol       Date:  2013-11-13

7.  Hyperlipidemia and Allograft Rejection.

Authors:  Jessamyn Bagley; Linus Williams; Michael Hyde; Christian Rosa Birriel; John Iacomini
Journal:  Curr Transplant Rep       Date:  2019-02-26

8.  Statin intensity and risk for cardiovascular events after heart transplantation.

Authors:  Jessica R Golbus; Sarah Adie; Matheos Yosef; Venkatesh L Murthy; Keith D Aaronson; Matthew C Konerman
Journal:  ESC Heart Fail       Date:  2020-06-24

9.  Proinflammatory protein signatures in cryptogenic and large artery atherosclerosis stroke.

Authors:  Lukas Holmegaard; Tara M Stanne; Ulf Andreasson; Henrik Zetterberg; Kaj Blennow; Christian Blomstrand; Katarina Jood; Christina Jern
Journal:  Acta Neurol Scand       Date:  2020-12-04       Impact factor: 3.209

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.